TP Group PLC - Result of Court Meeting & General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION
RECOMMENDED CASH ACQUISITION
of
TP Group plc
("TP Group" or the "Company")
by
Science Group plc
("Science Group")
to be effected by way of scheme of arrangement
under Part 26 of the Companies Act 2006 ("Companies Act")
RESULT OF COURT MEETING AND GENERAL MEETING
On
Further to the publication of the Scheme (the "Scheme Document") by TP Group and Science Group on
(1) the requisite majority of Scheme Shareholders voted (either in person or by proxy) in favour of the Scheme, being a majority in number of Scheme Shareholders, who were present, entitled to vote and voted (either in person or by proxy) and who together represented not less than 75% of the votes cast at the Court Meeting; and
(2) the requisite majority of TP Group Shareholders voted (either in person or by proxy) in favour of the Special Resolution to implement the Scheme, including the amendments to the TP Group Articles, at the General Meeting.
Details of the resolutions passed are set out in the Notices of the Court Meeting and General Meeting contained in the Scheme Document. Capitalised terms used in this announcement (the "Announcement") shall, unless otherwise defined, have the same meanings as set out in the Scheme Document.
Voting results of the Court Meeting
Each Scheme Shareholder present (in person or by proxy) was entitled to one vote per Scheme Share held at the Voting Record Time. Results of the poll at the Court Meeting held at
|
Results of Court Meeting |
No. of Scheme Shareholders who voted** |
% of Scheme Shareholders who voted* |
No. of Scheme Shares voted |
% of Scheme Shares voted* |
No. of Scheme Shares voted as a % of the total Scheme Shares |
|
FOR*** |
62 |
81.58 |
319,008,853 |
98.79 |
57.84 |
|
AGAINST |
14 |
18.42 |
3,905,373 |
1.21 |
0.71 |
|
TOTAL |
76 |
100 |
322,914,226 |
100 |
58.55 |
The total number of Scheme Shares in issue at the Voting Record Time was 551,548,715.
Voting results of the General Meeting
Each Shareholder present (in person or by proxy) was entitled to one vote per Share held at the Voting Record Time. Results of the poll at the General Meeting held at
|
|
No. of Shares voted |
% of Shares voted* |
% of total voting rights |
|
FOR*** |
319,940,673 |
98.77 |
41.06 |
|
AGAINST |
3,984,059 |
1.23 |
0.51 |
|
WITHHELD**** |
451,123 |
n/a |
0.06 |
|
TOTAL |
324,375,855 |
100 |
41.63 |
* Rounded to two decimal places.
** The total number of Scheme Shareholders who voted includes 9 Scheme Shareholders who gave instructions for votes to be cast in favour of the resolution in respect of part of their holding and against the resolution in respect of another part of their holding ("Split Voting"). The total numbers of Scheme Shareholders voting for or against the Resolution by proxy therefore exceeds the related total of those Scheme Shareholders present and voting because where Scheme Shareholders have cast Split Voted, they have been counted towards both the number of votes cast in favour of the Resolution and the number of votes cast against.
*** Incorporates proxy appointments which gave discretion to the Chair of the General Meeting.
**** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against' the resolution.
The total number of Shares in issue at the Voting Record Time was 779,178,719. The Company does not hold any Shares in treasury. Therefore, the total number of voting rights in TP Group at the Voting Record Time were 779,178,719.
Expected timetable to completion
The Scheme Document contains an expected timetable of principal events for the implementation of the Scheme. Completion of the Scheme now remains conditional on the satisfaction or (if capable of waiver) waiver of the other Conditions set out in the Scheme Document, including the sanction of the Court at the Court Hearing, which is expected to take place in the early part of Q1 2023, subject to Science Group obtaining (or waiving) the NSIA and FATA clearances, and, in any event, prior to
|
The following dates are indicative only and are subject to change |
|
|
Court Hearing |
a date expected to be in the early part of Q1 2023, subject to NSIA and FATA clearances, and, in any event, prior to |
|
Last day of dealings in, and for registration of transfers of, and disablement in CREST of, Shares |
D+1 Business Day |
|
Scheme Record Time |
|
|
Effective Date ("ED") of the Scheme |
D+2 Business Days ("ED") |
|
Suspension of Shares to trading on AIM |
|
|
Cancellation of admission to trading of Shares on AIM |
by |
|
Latest date for despatch of cheques or settlement through CREST in respect of the cash consideration. |
within 14 days of the ED |
|
Long-stop Date |
20 April 2023 |
Cancellation of admission of TP Group to trading on AIM
The Company will announce the final timetable containing firm dates once the date of the relevant regulatory clearances (detailed below) have been confirmed (the "Timetable Announcement"). At that point, TP Group expects to make an application to the London Stock Exchange for the Shares to cease to be admitted to trading on AIM with effect from the Business Day following the Effective Date of the Scheme, subject to the sanction of the Court at the Court Hearing once Science Group has obtained (or waived) the NSIA and FATA clearances. If the Scheme becomes Effective in accordance with its terms, it is currently expected that trading on AIM of TP Group Shares will be suspended at
The Scheme is expected to become Effective in Q1 2023. TP Group will make further announcements through a Regulatory Information Service, with such announcements also being made available on the TP Group website: www.tpgroupglobal.com/investors, in relation to the expected timetable as appropriate in respect of the NSIA and FATA clearances upon which the Acquisition is conditional.
Information for TP Group Shareholders
If you are in any doubt as to the action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000 if you are in the
All references to times in this Announcement are to
|
Enquiries: |
|
|
TP Group plc |
Tel: +44 (0) 1753 285802 |
|
|
|
|
Cenkos Securities plc, financial adviser, nominated adviser and broker to TP Group |
Tel: +44 (0) 20 7397 8980 |
|
|
|
|
Science Group plc |
|
|
|
Tel: +44 (0) 1223 875 200 |
|
Stifel Nicolaus Europe Limited, exclusive financial adviser, nominated adviser and joint broker to Science Group ("Stifel") |
|
|
|
Tel: +44 (0) 207710 7600 |
|
Liberum Capital Limited, Joint Broker to Science Group ("Liberum") |
|
|
|
Tel: +44 (0) 20 3100 2000
|
Publication on website
In accordance with Rule 26.1 of the Code, a copy of this announcement will be available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on TP Group's website at www.tpgroupglobal.com/investors and on Science Group's website at www.sciencegroup.com/investor-information/, by no later than 12.00 noon (
The content of the website referred to above is not incorporated into and does not form part of this announcement.
Important notice
This Announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, whether pursuant to this Announcement or otherwise, or the solicitation of any vote or approval of any offer in any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction and any such offer (or solicitation) may not be extended in any such jurisdiction.
Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended, or with any securities regulatory authority of any state of
This Announcement has been prepared in accordance with the laws of
Cenkos, which is authorised and regulated in the
Stifel, which is authorised and regulated in the
Liberum, which is authorised and regulated in the
Disclosure requirements of the Takeover Code (the "Code")
Disclosure requirements of the Code
Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than
Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than
If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE